![]() |
市场调查报告书
商品编码
1576516
止血剂市场规模、占有率、预测和趋势分析:按类型、应用和最终用户划分 - 到 2031 年的全球预测Hemostats Market Size, Share, Forecast, & Trends Analysis by Type Form Application End User - Global Forecast to 2031 |
预计到 2031 年,止血剂市场将达到 53.2 亿美元,2024 年至 2031 年的复合年增长率为 6.9%。
本报告在广泛的二级和一级研究以及对市场情景的详细分析后,对主要市场推动因素、阻碍因素、课题和机会进行了分析。该市场的成长是由癌症、心血管疾病、骨科疾病、神经系统疾病等慢性病患病率上升以及相关的手术量增加、事故率上升、剖腹产数量增加所推动的。活动的增加、医疗保健成本的上升以及对微创手术的日益偏好。然而,止血剂所用材料引起的过敏反应限制了该市场的成长。
此外,先进止血剂的使用不断增加、牙科止血剂的进步以及对预装施药器和 RTU 止血剂的需求不断增加,预计将为在该市场运营的公司提供增长机会。然而,止血剂的高製造成本和先进抗菌止血剂的高成本是影响市场成长的主要课题。
(註:提供上位5公司的SWOT分析)
Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User- Global Forecast to 2031
The hemostat market is projected to reach $5.32 billion by 2031 at a CAGR of 6.9% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. However, allergic reactions caused by the material used in making hemostats restrain the growth of this market.
Furthermore, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to generate growth opportunities for the players operating in this market. However, the high manufacturing cost for hemostasis and the high cost of advanced antimicrobial hemostatic agents are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the hemostat market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.).
Among all the types studied in this report, in 2024, the absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostat market. The segment's large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.
Among all the applications studied in this report, in 2024, the surgery segment is expected to account for the larger share of the hemostat market. The largest market share of this segment is attributed to the increasing number of surgeries, rise in the number of accidents, and growing demand for cosmetic/plastic surgeries. For instance, according to the World Health Organization (WHO), in 2021, yearly, 4.4 million people died from injuries, 3.16 million died from accidental wounds, and 1.25 million died from violence-related injuries globally.
Among all the forms studied in this report, in 2024, the matrix and gel segment is expected to account for the largest share of the hemostat market. The segment's large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.
Among all the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostat market. The growing number of surgeries conducted in hospitals, the use of hemostats for control of minor, moderate, and severe bleeding in operating rooms, the availability of different forms of hemostats used for surgical procedures, and the availability of favorable reimbursement policies are some of the major factors driving the growth of this segment.
An in-depth analysis of the geographical scenario of the hemostat market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 32.9% of the hemostat market. In the region in 2024, the U.S. is expected to account for the largest share of the hemostat market in North America. The large share of this regional market is attributed to the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.
Hemostat Market Assessment-by Type
Hemostat Market Assessment-by Application
Hemostat Market Assessment-by Form
Hemostat Market Assessment-by End User
Hemostat Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)